SOP for Preparation of Nanocrystals for Drug Delivery

Standard Operating Procedure for Preparation of Nanocrystals for Drug Delivery

1) Purpose

This SOP describes the process for preparing drug nanocrystals, which enhance the solubility and bioavailability of poorly water-soluble drugs. The goal is to standardize the preparation of nanocrystals for drug delivery applications.

2) Scope

This SOP applies to all laboratory staff involved in the formulation and preparation of drug nanocrystals for pharmaceutical and drug delivery purposes.

3) Responsibilities

Operators: Responsible for following the SOP to prepare nanocrystals according to the specified protocols.
QA: Ensures compliance with the protocol and verifies the quality of prepared nanocrystals.

4) Procedure

4.1 Preparation of Drug Solution

4.1.1 Drug Selection and Dissolution

4.1.1.1 Select the poorly water-soluble drug to be formulated into nanocrystals.
4.1.1.2 Dissolve the drug in an organic solvent or a mixture of organic solvents suitable for the nanocrystal formulation.

4.2 Nanocrystal Formation

4.2.1 Precipitation Method

4.2.1.1 Add the drug solution dropwise into an aqueous phase containing stabilizers while continuously stirring to precipitate the drug nanocrystals.
4.2.1.2 Maintain stirring for 15–30 minutes until nanocrystals are formed.

4.2.2 High-Pressure Homogenization

4.2.2.1 Homogenize the suspension at high pressure to reduce the particle size and achieve nanoscale dimensions.
4.2.2.2 Monitor the size reduction using dynamic light scattering (DLS) or another particle-sizing method.

4.3 Washing and Collection of Nanocrystals

4.3.1 Filtration

4.3.1.1 Filter the nanocrystal suspension using a filtration unit to remove any remaining organic solvents.
4.3.1.2 Wash the nanocrystals with distilled water to remove any excess stabilizers or solvents.

4.3.2 Centrifugation

4.3.2.1 Centrifuge the suspension to collect the nanocrystals, discarding the supernatant.
4.3.2.2 Repeat the washing and centrifugation process as needed to ensure the purity of the nanocrystals.

4.4 Characterization of Nanocrystals

4.4.1 Particle Size Measurement

4.4.1.1 Measure the particle size using DLS or other appropriate methods to confirm that the nanocrystals meet the desired size specifications.

4.5 Storage of Nanocrystals

4.5.1 Storage Conditions

4.5.1.1 Store the nanocrystals in sealed, sterile containers at 4°C or room temperature, depending on stability data.

5) Abbreviations, if any

DLS: Dynamic Light Scattering

6) Documents, if any

Nanocrystal Preparation Logbook

7) References, if any

Guidelines for preparing drug nanocrystals for pharmaceutical use

8) SOP Version

Version 1.0

Annexure

Nanocrystal Preparation Logbook Template


  
    Date
    Batch Number
    Drug Used
    Particle Size
    Stability Test
    Operator Initials
    QA Initials
  
  
    DD/MM/YYYY
    Batch Number
    Drug Name
    Size in nm
    Pass/Fail
    Operator Name
    QA Name

Date	Batch Number	Drug Used	Particle Size	Stability Test	Operator Initials	QA Initials
DD/MM/YYYY	Batch Number	Drug Name	Size in nm	Pass/Fail	Operator Name	QA Name